SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing significant volatility as investors weigh aggressive AI infrastructure expansion and a fuel cell partnership against broader software sector weakness. While some in the community see the current price action as a strategic shakeout of weak hands, others remain cautious due to concerns over high debt and shifting sentiment toward AI-driven software.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is experiencing intense trading activity driven by reports of Amazon entering advanced buyout talks to bolster its satellite internet network. While the community is actively debating the potential for a bidding war involving major sector players, many long-term shareholders are pushing back against lower valuation figures, emphasizing the strategic scarcity of the company's spectrum assets and its established partnership with Apple.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is currently trending as investors digest a major long-term deal with Google to develop custom AI chips and an expanded partnership with Anthropic, sparking debate over whether the stock's valuation fully reflects its role as a core infrastructure enabler. Community discussions are split between those viewing the partnership as a long-term catalyst for growth and others skeptical of the broader semiconductor sector's ability to maintain high AI-driven demand amidst market volatility.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending as shareholders react to a bullish letter from CEO Andy Jassy, which revealed significant growth in AWS AI services and custom silicon revenue. The community is actively discussing the company's massive capital expenditure plans and potential for infrastructure dominance, fueling optimistic sentiment around its long-term positioning against other tech heavyweights.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending due to a flurry of positive catalysts, including a landmark partnership with the University of Cambridge and a new stock registration filing that has kept trading volume high. The community is actively debating the stock's future, balancing enthusiasm for its quantum networking and hardware progress against concerns over dilution and high volatility as the sector experiences significant revaluation.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is experiencing heightened volatility driven by the expansion of its robotaxi partnership with Uber and the announcement of a significant capital raise, even as investors debate the impact of the newly appointed CEO. Community sentiment remains polarized, with many traders focusing on potential dilution and production hurdles while others look toward the company's long-term pivot to a mainstream, higher-volume vehicle platform.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal Holdings is currently a major focus for traders as the stock experiences tight consolidation following a period of intense volatility and analyst scrutiny. Investors are actively debating the company's long-term valuation relative to its aggressive share buyback programs, while speculating on potential strategic shifts or M&A activity under new leadership.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. The firm focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending as investors weigh strong core banking operations against concerns over slowing loan growth, credit provisions, and management's cautious commentary on geopolitical and economic risks. The community remains divided, with some traders focused on the stock's resilience and institutional positioning, while others emphasize broader sector headwinds and potential downside risks in the current rate environment.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing massive volatility and elevated short interest, drawing comparisons to previous meme stock squeezes as retail investors debate whether the parabolic price action is driven by fundamental momentum or an unsustainable short-squeeze trap. The community is sharply divided, with bulls pointing to historical squeeze patterns and potential sector rotation, while bears highlight deteriorating fundamentals and the risks of holding through highly overbought technical levels.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics is experiencing significant market volatility driven by the FDA's decision to hold an Advisory Committee meeting regarding the supplemental application for Filspari in FSGS. While some investors are expressing concern over the regulatory timeline, the community remains divided, with many long-term holders viewing the pullback as a buying opportunity, citing institutional backing and the drug's foundational status in rare kidney disease treatment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>REPL came under pressure after the FDA issued a second Complete Response Letter for RP1 with nivolumab in anti-PD-1-failed melanoma.</li><li>HOTH declined after a $2 million stock offering, along with attached warrants, raised dilution concerns despite recent pipeline updates.</li><li>ONCO is on a major slide after its reverse stock split, while its pending all-stock acquisition of Realbotix has yet to improve investor sentiment.</li></ul>Shares of Replimune (REPL), Hoth Therapeutics (HOTH), and Onconetix (ONCO) hit fresh 52-week lows on Monday following an FDA setback, a discounted offering, and a reverse split that underscored listing-compliance pressure.&nbsp;On Monday,&nbsp;<a href="https://stocktwits.com/symbol/REPL">REPL</a> fell 64%,&nbsp;<a href="https://stocktwits.com/symbol/HOTH">HOTH</a> slipped 1% and&nbsp;<a href="https://stocktwits.com/symbol/ONCO">ONCO</a> declined 27%, while the Health Care Select Sector SPDR Fund (XLV) rose 0.5%.<h2 class="st-heading-2">Regulatory Setback Pressures REPL Shares Again</h2>Pressure on REPL intensified recently after the U.S. Food and Drug Administration (FDA) issued a second Complete Response Letter (CRL) for its lead drug RP1 in combination with Nivolumab in anti-PD-1-failed melanoma, extending regulatory uncertainty that had already followed an earlier CRL last year.The latest development triggered a wave of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/repl-stock-on-track-to-hit-all-time-lows-here-s-why-this-analyst-slashed-price-target-by-85/cZJFHklRIMD">analyst downgrades</a> across Wall Street. Jefferies said the company faces “a tough road ahead” following the FDA’s response, while BMO Capital said the CRL “lays bare the lack of alignment with the FDA and Replimune” throughout clinical development and warned the revised regulatory pathway may now require additional trials.JPMorgan called the outcome “disappointing,” adding it had previously believed “the totality of the data for RP1 warranted an approval.”&nbsp;<h2 class="st-heading-2">Stock Offering Weighs On HOTH Stock</h2>HOTH declined after the company announced earlier this month a stock offering priced at $0.7 per share, expected to generate about $2 million in gross proceeds before expenses, along with warrants exercisable at $0.85.The financing overshadowed pipeline updates over the past month, when the company reported interim Phase 2 progress for HT-001, a topical therapy to treat skin toxicities caused by epidermal growth factor receptor (EGFR) inhibitor cancer treatments. The trial showed that patients reached the primary efficacy endpoint by the sixth week and demonstrated “strong patient benefit across multiple clinically meaningful measures.”&nbsp;However, shares caught a break in after-hours trading on Monday, jumping over 60%, after preclinical data showed its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-hoth-stock-up-after-hours-today/cZJ8gnKRIuz">HT-VA (GDNF) therapy</a> improved key gene markers linked to fat production and metabolism and outperformed Novo Nordisk's semaglutide on liver-fat regulation signals.<h2 class="st-heading-2">ONCO Slides Despite Realbotix Merger Progress</h2>ONCO shares have remained weak since the company implemented a 1-for-5 reverse stock split, effective March 25, to maintain compliance with Nasdaq’s minimum bid price requirement.The reverse split followed a September equity raise of $12.9 million through Series D preferred stock and warrants, with proceeds used in part to reduce outstanding debt and support working capital following the termination of a previously planned merger with Ocuvex.In February, the company entered into an agreement to acquire Realbotix in an all-stock transaction expected to close in the second half of 2026. Realbotix reported delivering its first Vinci-equipped humanoid robot to Ericsson this month and said the platform enables robots to “recognize returning users, recall previous conversations, and track engagement.” The company expects deliveries of 19 robots across March, April and May as production scales.<h2 class="st-heading-2">How Do Retail Traders Feel About REPL, HOTH, ONCO?</h2>On Stocktwits, retail sentiment for REPL was ‘bearish’ amid ‘extremely high’ message volume, while sentiment for both HOTH and ONCO remained ‘extremely bullish,’ also accompanied by ‘extremely high’ message volume.Over the past year, REPL has fallen 77%, HOTH down 36% and ONCO declining 97%, with all three stocks underperforming the broader XLV ETF, which rose 10% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/immunitybio-founder-fda-warning-letter-anktiva-ad-never-aired/cZJpYnYRIHR">ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All'</a>

On Monday alone, REPL plunged 64%, ONCO dropped 27%, and HOTH slipped 1%. (Photo credit: Getty Images)

REPL, HOTH, ONCO Stocks Hit 52-Week Lows: What's Driving The Selloff In These Biotech Plays?

On Monday alone, REPL plunged 64%, ONCO dropped 27%, and HOTH slipped 1%, underperforming the broader XLV healthcare ETF.

Equity

Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes

REPL stock plunges after a second FDA CRL delays RP1 melanoma approval, casting doubt on its regulatory path and near-term growth plans.

Cantor Fitzgerald Reaffirms Neutral Rating for Replimune Group (NASDAQ:REPL)

Cantor Fitzgerald reissued a "neutral" rating on shares of Replimune Group in a research report on Monday...

Replimune Group (NASDAQ:REPL) Lowered to "Underperform" Rating by BMO Capital Markets

BMO Capital Markets cut Replimune Group from a "market perform" rating to an "underperform" rating and set a $1.00 price objective for the company. in a report on Monday...

Replimune Group (NASDAQ:REPL) Earns "Market Perform" Rating from Leerink Partners

Leerink Partners restated a "market perform" rating and issued a $2.00 price target (down from $11.00) on shares of Replimune Group in a research note on Monday...

JPMorgan Chase & Co. Reaffirms Underweight Rating for Replimune Group (NASDAQ:REPL)

JPMorgan Chase & Co. restated an "underweight" rating on shares of Replimune Group in a research note on Monday...

Replimune Group (NASDAQ:REPL) Receives "Neutral" Rating from Wedbush

Wedbush reissued a "neutral" rating and set a $2.00 target price (down from $19.00) on shares of Replimune Group in a research note on Monday...

Replimune Group's (REPL) "Hold" Rating Reiterated at Jefferies Financial Group

Jefferies Financial Group reissued a "hold" rating and issued a $2.00 target price (down from $13.00) on shares of Replimune Group in a research note on Monday...

Replimune Group (NASDAQ:REPL) Given Sell Rating at HC Wainwright

HC Wainwright reissued a "sell" rating on shares of Replimune Group in a research note on Monday...

Fastenal, Replimune Group, Children's Place And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures lower, with Dow futures down 150 points. Fastenal shares dip 4% after meeting earnings estimate. Other stocks also down.read more...

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Start of a real move higher

Dead cat - we retest the lows

Show me the results

Software is bouncing hard today. Is this the start of a sustained recovery or just a dead cat bounce before we retest the lows?

REPL
Replimune Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest REPL News

REPLReplimune Group Inc